Skip to content

Medical emergency? What to do

Tamoxifen curbs breast cancer risk, study confirms

3-RXPublished November 16, 20053 min read

Key points

  • Data from additional years of follow-up of a large study of tamoxifen for the prevention of breast cancer confirm that the drug reduces the risk of the disease in high-risk women.
  • In the study, which began in 1992, a total of 13,388 women aged 35 years or older who were at high risk for breast cancer due to family history and other factors were randomly assigned in a blinded fashion to receive either a placebo or tamoxifen for 5 years.
  • Tamoxifen was also found to reduce the risk of osteoporotic fractures but to increase the risks of endometrial cancer and thromboembolism (blood clots).
  • The latest data from the trial reported this week shows that the benefits and most undesirable effects of tamoxifen remain.

Data from additional years of follow-up of a large study of tamoxifen for the prevention of breast cancer confirm that the drug reduces the risk of the disease in high-risk women.

Tamoxifen "remains the only proven chemopreventive treatment for breast cancer risk reduction," Dr. Bernard Fisher, from the University of Pittsburgh, and colleagues note in their report in the Journal of the National Cancer Institute this week.

In the study, which began in 1992, a total of 13,388 women aged 35 years or older who were at high risk for breast cancer due to family history and other factors were randomly assigned in a blinded fashion to receive either a placebo or tamoxifen for 5 years.

In 1998, when the study was "unblinded," researchers observed that women taking tamoxifen had a 49 percent lower risk of developing breast cancer.

Tamoxifen was also found to reduce the risk of osteoporotic fractures but to increase the risks of endometrial cancer and thromboembolism (blood clots).

At the time the study was unblinded, the women who were taking placebo were given the option of starting tamoxifen.

The latest data from the trial reported this week shows that the benefits and most undesirable effects of tamoxifen remain. That is, after 7 years of follow-up, using tamoxifen rather than placebo reduced the cumulative rate of invasive cancer by 43 percent, from 42.5 cases per 1,000 women in the placebo group to 24.8 cases per 1,000 women in the tamoxifen group.

The rate of noninvasive breast cancer was reduced by 37 percent, from 15.8 cases per 1,000 women in the placebo group to 10.2 cases per 1,000 women in the tamoxifen group. These changes were similar in magnitude to that seen in the initial report.

Tamoxifen use was also associated with a 32 percent reduction in the risk of fractures, the findings indicate.

In general, tamoxifen raised the risk of adverse events, such as blood clots and cataracts, to a similar extent as in the initial report. The exceptions were a lower risk of developing blood clots in the lungs and a higher risk of endometrial cancer, but the differences fell short of statistical significance. The risk of lung blood clots was about 11 percent lower and the risk of endometrial cancer was about 29 percent higher than first reported, but, again, these differences were not significant.

According to Fisher and colleagues, a series of breast cancer prevention trials now in progress are evaluating other agents that "could be more effective than tamoxifen in curbing the risk of breast cancer and reducing the frequency of undesirable side effects noted with the drug."

However, "until one of these trials demonstrates a greater net benefit from an alternative therapy, tamoxifen remains the only proven chemopreventive treatment for breast cancer risk reduction."

SOURCE: Journal of the National Cancer Institute, November 15, 2005.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underBreast Cancer
Cancer

Strong social ties benefit breast cancer patients

Breast cancer patients who have a strong social support system in the first year after diagnosis are less likely to die or have a recurrence of cancer, according to new research from Vanderbilt-Ingram Cancer Center…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.